Innovations in clinical neuroscience最新文献

Objective: Intellectual disability (ID) is considered one of the most common human disorders characterized by significant deficits in cognition and functional and adaptive skills. The aims of this study were to describe the demographic and clinical features of a group of Moroccan individuals with ID living in the Tangier-Tetouan region.

Design: This was a retro-prospective and descriptive exploratory monocentric study realized between November 2020 and August 2023. A total of 109 patients with ID were included. They were selected at four mental health centers in the Tangier-Tetouan region. Our data were treated and analyzed using the IBM SPSS version 26.

Results: A male predominance of patients with ID was observed in our series (54.4% male vs. 42.6% female). The male-to-female ratio was 1.34. The mean±standard deviation (SD) age of our patients was 11.75±4.87 years, ranging from 1 to 35 years. The mean ages of mothers and fathers at the births of their children with ID were 28.36 and 35.6 years, respectively. Many co-occurring medical conditions were noted in our data (speech delay: 20.5%, concentration problems: 15.1%, hyperactivity: 11.1%, ambulation difficulties: 8.8%, aggressiveness: 8%, vision problems: 6.3%, epileptic seizures: 4%). The consanguinity rate was 26.9 percent.

Conclusion: ID associated with genetic causes was significantly correlated with the consanguinity rate in the Moroccan population.

Introduction: Well-known adverse events of antipsychotics are movement disorders, or extrapyramidal symptoms, such as drug-induced parkinsonism and tardive dyskinesia.

Objective: With new evidence suggesting a link between low high-density lipoprotein cholesterol (HDL-C) and risk of Parkinson's disease, this study sought to investigate if that link also translated to patients taking antipsychotics with low HDL-C and an increased risk for developing a movement disorder.

Design: Adult patients (n=89) at an inpatient state psychiatric facility taking at least one antipsychotic with at least one HDL-C level were assessed for signs of a movement disorder through their history and physical, progress notes, and Abnormal Involuntary Movement Scale (AIMS) score.

Results: There was no statistical significance when comparing a patient's movement disorder, AIMS scores, and HDL-C levels to suggest that the HDL-C level influenced a patient's movement disorder.

Conclusion: This study did not show a correlation between HDL-C levels and a patient's risk of developing a movement disorder while taking an antipsychotic.

This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers might provide different advice, and readers should take this into consideration. The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. Note: The information and recommendations in this article are applicable to physicians and other health care professionals so "clinician" is used to indicate all treatment team members.

Glucagon-like peptide-1 (GLP-1) receptor agonists have garnered significant attention in diabetes management, and they act by mimicking the effects of GLP-1, a hormone that regulates insulin secretion and appetite. While these medications have become increasingly popular, their impact on mood and other psychiatric manifestations remains uncertain because of inconsistent data. It has been shown to affect brain regions involved in emotional regulation. This case report underscores the adverse mood changes possibly linked to semaglutide and the need for further study in this area.

The Social Interaction Anxiety Scale (SIAS) is a globally used scale for clinical diagnostic purposes for social anxiety disorder (SAD). This article investigates the psychometric properties of the SIAS, followed by its adaptation and validation in Urdu. The study consisted of two phases. The initial phase involved the translation of the scale, and the second phase was of a cross-sectional nature and consisted of evaluating factor structure and psychometric properties of the scale. For this purpose, the study enrolled a purposive sample of 573 adults aged between 18 to 45 years (mean [standard deviation (SD)] age: 23.68 [4.28] years) with a diagnosis of SAD. The sample was recruited from educational institutes, hospitals, and clinics in Lahore, Pakistan. The data was collected using a demographic form and the Urdu version of the SIAS, along with the Multidimensional Psychological Flexibility Inventory (MPFI). The analyses of the study were carried out using SPSS V27 and AMOS V24. Confirmatory factor analysis revealed a single factor structure of the Urdu version of the SIAS consisting of 16 items. The psychometric values of the scale shown were excellent, as Cronbach's alpha equaled 0.91, convergent validity r equaled 0.37 at p less than 0.01 with psychological inflexibility, and discriminant validity r equaled -0.47 at p less than 0.01 with psychological flexibility. The study concluded that the Urdu version of the SIAS was a valid and reliable measure for the assessment of social anxiety in the Pakistani population.

Mental health providers sometimes encounter patients who are exceptionally altruistic toward others and, at the same time, are willing to ignore their own needs and even significantly harm themselves to best achieve these ends for others. Traditionally, therapists have seen it to be their role to discern patients' negative symptoms, then seek to reduce them. This article reviews gains based on positive psychology that highlight the importance of therapists giving priority to supporting patients' strengths, particularly the sources of meaning they have in their lives. As is consistent with this view, it is suggested that therapists working with this group of self-harming, altruistic patients not only support their altruism, but particularly consider and remain cautious as to whether or not they should explore unconscious factors with the patient that might fuel their altruism. It is suggested that the discovery of such factors might be harmful because it could risk decreasing the degree to which these patients continue to show and personally value their altruism, thus potentially decreasing the meaning they derive from their altruism.